Population pharmacokinetic modeling confirms appropriate dosing of oxcarbazepine for children, regardless of obesity status.
A model-informed analysis confirms that the current pediatric dosing regimen of OXZ applies to children in general, regardless of their obesity status.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: